Use of dialytic therapies for poisoning

  • James F. Winchester
  • Nikolas Harbord
  • Donald A. Feinfeld

The nephrologist is often consulted in poisoning cases. Although management may involve attention to incident renal failure or electrolyte and acid-base disorders, blood purification may also be necessary [1]. The application of dialysis therapies or hemoperfusion to enhance clearance of intoxicants is an essential task for the nephrologist.

This chapter will outline the principles and use of dialysis and related procedures for the treatment of the poisoned patient. Consideration will be given to criteria for use of dialysis and related modalities, decision among available options, and recent advances. Finally, detailed discussion will follow for specific poisonings for which dialysis therapies are especially effective.


Peritoneal Dialysis Continuous Renal Replacement Therapy Dialytic Therapy Therapeutic Plasma Exchange Blood Purification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Watson WA, Litovitz TL, Rodgers Jr. GC, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23:589-666PubMedGoogle Scholar
  2. 2.
    Linquette, Goudemande, Warot, et al. Acute poisoning by sodium chlorate; anuria; exchange transfusions and peritoneal dialysis. Echo Med Nord. 1950;21:269-276.PubMedGoogle Scholar
  3. 3.
    Brown IA. The use of hemodialysis in the treatment of barbiturate intoxication Minn Med. 1954;37:650-652Google Scholar
  4. 4.
    Peces R, Fernandez EJ, Regidor D, et al. Treatment of acute lithium intoxication with high-flux haemodialysis membranes. Nefro-logia. 2006;26:372-378Google Scholar
  5. 5.
    Palmer BF. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis. 2000;36:640-643PubMedGoogle Scholar
  6. 6.
    Wrathall G, Sinclair R, Moore A, et al. Three case reports of the use of haemodiafiltration in the treatment of salicylate overdose. Hum Exp Toxicol. 2001;20:491-495PubMedGoogle Scholar
  7. 7.
    Feinfeld DA, Rosenberg JW, Winchester JF. Three controversial issues in extracorporeal toxin removal. Semin Dial. 2006;19:358-362PubMedGoogle Scholar
  8. 8.
    Betten DP, Vohra RB, Cook MD, et al. Antidote use in the critically ill poisoned patient.J Intensive Care Med. 2006;21:255-277PubMedGoogle Scholar
  9. 9.
    Vale JA, Kulig K. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42:933-943PubMedGoogle Scholar
  10. 10.
    Position paper: Ipecac syrup. J Toxicol Clin Toxicol. 2004;42:133-143Google Scholar
  11. 11.
    Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42:843-854Google Scholar
  12. 12.
    Position paper: cathartics. J Toxicol Clin Toxicol. 2004;42:243-253Google Scholar
  13. 13.
    Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005;43:61-87Google Scholar
  14. 14.
    Proudfoot AT, Krenzelok EP, Vale JA, et al. Position Paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42:1-26PubMedGoogle Scholar
  15. 15.
    Garrettson LK; Geller RJ. Acid and alkaline diuresis. When are they of value in the treatment of poisoning? Drug Saf. 1990;5:220-232PubMedGoogle Scholar
  16. 16.
    El Minshawy O, Abd El Aziz T, Abd El Ghani H. Evaluation of vascular access complications in acute and chronic hemodialysis. J Vasc Access. 2004;5:76-82PubMedGoogle Scholar
  17. 17.
    Sulowicz W, Radziszewski A. Pathogenesis and treatment of dialysis hypotension. Kidney Int Suppl. 2006;104:S36-39Google Scholar
  18. 18.
    Silver SM. Cerebral edema after rapid dialysis is not caused by an increase in brain organic osmolytes. J Am Soc Nephrol. 1995;6:1600-1606PubMedGoogle Scholar
  19. 19.
    Maher JF.Principles of dialysis and dialysis of drugs. Am J Med. 1977;62:475PubMedGoogle Scholar
  20. 20.
    Gibson TP, Atkinson AI. Effect of changes in inter compartment rate constants on drug removal duri ng hemoperfusion. J Pharm Sci. 1978; 67:1178PubMedGoogle Scholar
  21. 21.
    Furst DE, Tozer TN, Melmon KL. Salicylate clearance, the resultant of protein binding and metabolism. Clin Pharmacol Ther. 1979;26:380-389PubMedGoogle Scholar
  22. 22.
    Vincent HH, Vos MC, Akcahuseyin AE, et al. Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif. 1993;11:99-107PubMedGoogle Scholar
  23. 23.
    Depner T, Garred L. Solute transport mechanisms in dialysis. in Replacement of Renal Function by Dialysis, 5th edition, editors Horl  W, Koch KM, Lindsay RM, Ronco C, Winchester JF. Kluwer Academic Publishers, Dordrecht, 2004:73-93Google Scholar
  24. 24.
    Liao Z, Zhang W, Hardy PA. Kinetic comparison of different acute dialysis therapies. Artif Organs. 2003;27:802-807PubMedGoogle Scholar
  25. 25.
    Goodman JW, Goldfarb DS. The role of continuous renal replacement therapy in the treatment of poisoning. Semin Dial.  2006;19:402-407PubMedGoogle Scholar
  26. 26.
    Pond SM. Extracorporeal techniques in the treatment of poisoned patients. Med J Aust. 1991;154:617-622PubMedGoogle Scholar
  27. 27.
    Jaeger A, Sauder P, Kopferschmitt J. When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. J Toxicol Clin Toxicol. 1993;31:429-447PubMedGoogle Scholar
  28. 28.
    Winek CL, Wahba WW, Winek CL Jr. Body distribution of ethchlorvynol. J Forensic Sci. 1989;34:687-690PubMedGoogle Scholar
  29. 29.
    Thompson TA, Vermeulen JD, Wagner WE Jr., et al. Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents. J Pharm Sci. 1981;70:1040-1043PubMedGoogle Scholar
  30. 30.
    Akil IO, Mir S. Hemodiafiltration for vancomycin overdose in a patient with end-stage renal failure. Pediatr Nephrol. 2001;16:1019-1021PubMedGoogle Scholar
  31. 31.
    Domoto DT, Brown WW, Bruggensmith P. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous he-mofiltration or continuous arteriovenous hemodiafiltration. Ann Intern Med. 1987;106:550-552PubMedGoogle Scholar
  32. 32.
    Borgeat A, Biollaz J, Freymond B, et al. Hemofiltration clearance of flecainide in a patient with acute renal failure. Intensive Care Med. 1988;14:236-237PubMedGoogle Scholar
  33. 33.
    Shalkham AS, Kirrane BM, Hoffman RS, et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis. 2006;48:239-241PubMedGoogle Scholar
  34. 34.
    Kawasaki CI, Nishi R, Uekihara S, et al. How tightly can a drug be bound to a protein and still be removable by charcoal hemop-erfusion in overdose cases? Clin Toxicol. 2005;43:95-99Google Scholar
  35. 35.
    Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med. 1997;4:674-678PubMedGoogle Scholar
  36. 36.
    Bouma AW, van Dam B, Meynaar IA, et al. Accelerated elimination using hemoperfusion in a patient with phenobarbital intoxica-tion. Ned Tijdschr Geneeskd. 2004;148:1642-1645PubMedGoogle Scholar
  37. 37.
    Yeo FE, Bohen EM, Yuan CM, et al. Therapeutic plasma exchange as a nephrological procedure: a single-center experience. J Clin Apher. 2005;20:208-216PubMedGoogle Scholar
  38. 38.
    Jander S, Bischoff J. Treatment of Amanita phalloides poisoning: I. Retrospective evaluation of plasmapheresis in 21 patients. Ther Apher. 2000;4:303-307PubMedGoogle Scholar
  39. 39.
    Jander S, Bischoff J, Woodcock BG. Plasmapheresis in the treatment of Amanita phalloides poisoning: II. A review and recom-mendations. Ther Apher. 2000;4:308-312PubMedGoogle Scholar
  40. 40.
    Yildirim C, Bayraktaroglu Z, Gunay N, et al. The use of therapeutic plasmapheresis in the treatment of poisoned and snake bite victims: an academic emergency department’s experiences. J Clin Apher. 2006;21:219-223PubMedGoogle Scholar
  41. 41.
    Choi JH, Oh JC, Kim KH, et al: Successful treatment of cisplatin overdose with plasma exchange. Yonsey Med J. 2002;43:128-132Google Scholar
  42. 42.
    Steffen C, Seitz R. Severe chlorate poisoning: report of a case. Arch Toxicol. 1981;48:281-288PubMedGoogle Scholar
  43. 43.
    Martinez MA, Ballesteros S, Almarza E, et al. Acute nitrobenzene poisoning with severe associated methemoglobinemia: iden-tification in whole blood by GC-FID and GC-MS. J Anal Toxicol. 2003;27:221-225PubMedGoogle Scholar
  44. 44.
    Southgate HJ, Masterson R. Lessons to be learned: a case study approach: prolonged methaemoglobinaemia due to inadvertent dapsone poisoning; treatment with methylene blue and exchange transfusion. J R Soc Health. 1999;119:52-55Google Scholar
  45. 45.
    Kwon SU, Lim SH, Rhee I, et al: Successful whole blood exchange by apheresis in a patient with acute cyclosporine intoxication without long-term sequelae. J Heart Lung Transplant. 2006;25:483-485PubMedGoogle Scholar
  46. 46.
    Becaria A, Campbell A, Bondy SC, et al. Aluminum as a toxicant. Toxicol Ind Health. 2002;18:309-320PubMedGoogle Scholar
  47. 47.
    Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int. 2001;59:746-753PubMedGoogle Scholar
  48. 48.
    Weiss LG, Danielson BG, Fellstrom B, et al. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency. Nephron. 1989;51:325-329PubMedGoogle Scholar
  49. 49.
    Bouchard NC, Malostovker I, Harbord N, et al. Acute aluminum encephalopathy: aluminum extraction with high flux hemodialysis is superior to charcoal hemoperfusion (abstract). Clin Toxicol. 2005;43:677-678Google Scholar
  50. 50.
    Rapoport J, Chaimovitz C, Abulfil A, et al. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO). Isr J Med Sci. 1987;23:1242-1246PubMedGoogle Scholar
  51. 51.
    Bia MJ, Cooper K, Schnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int. 1989;36:852-858PubMedGoogle Scholar
  52. 52.
    McCarthy JT, Milliner DS, Johnson WJ, et al. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med. 1990;74:257-276PubMedGoogle Scholar
  53. 53.
    Baker LR, Barnett MD, Brozovic B, et al. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine. Clin Nephrol. 1976;6:326-328.PubMedGoogle Scholar
  54. 54.
    McCarthy JT, Libertin CR, Mitchell JC 3rd, et al. Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy. Mayo Clin Proc. 1982;57:439-441PubMedGoogle Scholar
  55. 55.
    Chang TM, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet. 1983;2:1051-1053PubMedGoogle Scholar
  56. 56.
    Boelaert JR, Van Cutsem J, de Locht M, et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypy-ridinone chelators have no effect. Kidney Int. 1994;45:667-671PubMedGoogle Scholar
  57. 57.
    Takeda T, Yukioka T, Shimazaki S. Cupric sulfate intoxication with rhabdomyolysis, treated with chelating agents and blood purification.Intern Med. 2000;39:253-255PubMedGoogle Scholar
  58. 58.
    Dargan PI, Giles LJ, Wallace CI, et al. Case report: severe mercuric sulphate poisoning treated with 2, 3-dimercaptopropane-1-sulphonate and haemodiafiltration. Crit Care. 2003;7:R1-6.PubMedGoogle Scholar
  59. 59.
    Yoshida M, Satoh H, Igarashi M, et al. Acute mercury poisoning by intentional ingestion of mercuric chloride. Tohoku J Exp Med. 1997;182:347-352PubMedGoogle Scholar
  60. 60.
    Hantson P, Haufroid V, Buchet JP, et al. Acute arsenic poisoning treated by intravenous dimercaptosuccinic acid (DMSA) and combined extrarenal epuration techniques. J Toxicol Clin Toxicol. 2003;41:1-6 PubMedGoogle Scholar
  61. 61.
    Roger SD, Crimmins D, Yiannikis C, et al. Lead intoxication in an anuric patient: management by intraperitoneal EDTA. Aust N Z J Med. 1990;20:814-817PubMedGoogle Scholar
  62. 62.
    Mactier RA. Aluminum and deferoxamine kinetics in CAPD. Adv Perit Dial. 1991;7:26-29PubMedGoogle Scholar
  63. 63.
    Rinaldi S, Sera F, Verrina E, et al. Chronic peritoneal dialysis catheters in children: a fifteen-year experience of the Italian Registry  of Pediatric Chronic Peritoneal Dialysis. Perit Dial Int. 2004;24:481-486PubMedGoogle Scholar
  64. 64.
    Wong SN, Geary DF. Comparison of temporary and permanent catheters for acute peritoneal dialysis. Arch Dis Child.1988;63:827-831PubMedGoogle Scholar
  65. 65.
    Vale JA, Prior JG, O’Hare JP, et al. Treatment of ethylene glycol poisoning with peritoneal dialysis. Br Med J (Clin Res Ed).  1982;284:557Google Scholar
  66. 66.
    Islek I, Uysal S, Gok F, et al. Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate. Pediatr Nephrol. 2001;16:510-514PubMedGoogle Scholar
  67. 67.
    Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med. 1978;47:123-144.PubMedGoogle Scholar
  68. 68.
    Schiffl H, Weidmann P, Weiss M, et al. Dialysis treatment of acute chromium intoxication and comparative efficacy of peritoneal versus hemodialysis in chromium removal. Miner Electrolyte Metab. 1982;7:28-35PubMedGoogle Scholar
  69. 69.
    Kobayashi T, Unishi G, Matsuzaki S, et al. A survival case of acute chromic acid poisoning treated by peritoneal dialysis. Nippon Jinzo Gakkai Shi. 1984;26:1259-1261PubMedGoogle Scholar
  70. 70.
    Lois F, Wallemacq P, de Tourtchanninoff M, et al. Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med. 2006;13:361-363PubMedGoogle Scholar
  71. 71.
    Berkovitch M, Akilesh MR. Acute digoxin overdose in a newborn with renal failure: use of digoxin immune Fab and peritoneal dialysis. Ther Drug Monit. 1994;16:531-533PubMedGoogle Scholar
  72. 72.
    Czajka PA, Anderson WH, Christoph RA, et al. A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol. 1980;20:565-569PubMedGoogle Scholar
  73. 73.
    Sabto JK, Pierce RM, West RH, et al. Hemodialysis, peritoneal dialysis, plasmapheresis and forced diuresis for the treatment of quinine overdose. Clin Nephrol. 1981;16:264-268PubMedGoogle Scholar
  74. 74.
    Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001;(3): CD003013.Google Scholar
  75. 75.
    Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625-639PubMedGoogle Scholar
  76. 76.
    Arancibia A, Corvalan F, Mella F, et al. Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. Int J Clin Pharmacol Ther Toxicol. 1986;24:240-245PubMedGoogle Scholar
  77. 77.
    Heim W, Oelschlager H, Kreuter J, et al. Liberation of lithium from sustained release preparations. A comparison of seven regis-tered brands. Pharmacopsychiatry. 1994;27:27-31PubMedGoogle Scholar
  78. 78.
    Belanger DR, Tierney MG, Dickinson G. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann Emerg Med. 1992 Nov; 21(11):1312-1315PubMedGoogle Scholar
  79. 79.
    Plenge P, Stensgaard A, Jensen HV, et al. 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry. 1994;36:511-516PubMedGoogle Scholar
  80. 80.
    Waring WS. Management of lithium toxicity. Toxicol Rev. 2006;25:221-230PubMedGoogle Scholar
  81. 81.
    Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: Three cases and review of literature. Mov Disord. 2007;22:570-573PubMedGoogle Scholar
  82. 82.
    Peces R, Fernandez EJ, Regidor D, et al. Treatment of acute lithium intoxication with high-flux haemodialysis membranes. Nefro-logia. 2006;26:372-378Google Scholar
  83. 83.
    Davis JE. Are one or two dangerous? Methyl salicylate exposure in toddlers. J Emerg Med. 2007;32:63-69PubMedGoogle Scholar
  84. 84.
    Bochner F, Somogyi AA, Wilson KM. Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin Phar-macokinet. 1991;21:394-399Google Scholar
  85. 85.
    Wecker H, Laubert A. Reversible hearing loss in acute salicylate intoxication. HNO. 2004;52:347-351PubMedGoogle Scholar
  86. 86.
    Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital  management. Clin Toxicol (Phila). 2007;45:95-131Google Scholar
  87. 87.
    Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42:1-26PubMedGoogle Scholar
  88. 88.
    Davis LE, Hudson D, Benson BE, et al. Methanol poisoning exposures in the United States: 1993-1998. J Toxicol Clin Toxicol.  2002;40:499-505PubMedGoogle Scholar
  89. 89.
    Paasma R, Hovda KE, Tikkerberi A, et al. Methanol mass poisoning in Estonia: outbreak in 154 patients. Clin Toxicol (Phila).  2007;45:152-157Google Scholar
  90. 90.
    Graw M, Haffner HT, Althaus L, et al. Invasion and distribution of methanol. Arch Toxicol. 2000;74:313-321PubMedGoogle Scholar
  91. 91.
    Onder F, Ilker S, Kansu T, et al. Acute blindness and putaminal necrosis in methanol intoxication. Int Ophthalmol. 1998-1999;22:81-84PubMedGoogle Scholar
  92. 92.
    Hsu HH, Chen CY, Chen FH, et al. Optic atrophy and cerebral infarcts caused by methanol intoxication: MRI. Neuroradiology.  1997;39:192-194PubMedGoogle Scholar
  93. 93.
    Megarbane B, Borron SW, Faud FJ. Current recommendations for treatment of severe toxic alcohol poisonings. Intensive Care  Med. 2005;31:189-195PubMedGoogle Scholar
  94. 94.
    Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001;344:424-429PubMedGoogle Scholar
  95. 95.
    Hovda KE, Andersson KS, Urdal P, et al. Methanol and formate kinetics during treatment with fomepizole. Clin Toxicol (Phila).  2005;43:221-227Google Scholar
  96. 96.
    Moore DF, Bentley AM, Dawling S, et al. Folinic acid and enhanced renal elimination in formic acid intoxication. J Toxicol Clin  Toxicol. 1994;32:199-204PubMedGoogle Scholar
  97. 97.
    Hantson P, Haufroid V, et al. Formate kinetics in methanol poisoning. Hum Exp Toxicol. 2005;24:55-59PubMedGoogle Scholar
  98. 98.
    Hunderi OH, Hovda KE, Jacobsen D. Use of the osmolal gap to guide the start and duration of dialysis in methanol poisoning.  Scand J Urol Nephrol. 2006;40:70-74PubMedGoogle Scholar
  99. 99.
    Vasavada N, Williams C, Hellman RN, et al. Ethylene glycol intoxication: case report and pharmacokinetic perspectives. Pharma-cotherapy. 2003;23:1652-1658Google Scholar
  100. 100.
    Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol. 1986;1:309-334PubMedGoogle Scholar
  101. 101.
    Leth PM, Gregersen M. Ethylene glycol poisoning. Forensic Sci Int. 2005;155:179-184PubMedGoogle Scholar
  102. 102.
    Froberg K, Dorion RP, McMartin KE. The role of calcium oxalate crystal deposition in cerebral vessels during ethylene glycol  poisoning. Clin Toxicol (Phila). 2006;44:315-358Google Scholar
  103. 103.
    Stokes MB. Acute oxalate nephropathy due to ethylene glycol ingestion. Kidney Int. 2006;69:203PubMedGoogle Scholar
  104. 104.
    Meier M, Nitschke M, Perras B, et al. Ethylene glycol intoxication and xylitol infusion--metabolic steps of oxalate-induced acute  renal failure. Clin Nephrol. 2005;63:225-258PubMedGoogle Scholar
  105. 105.
    Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of  Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol. 1999;37:537-560PubMedGoogle Scholar
  106. 106.
    Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols  Study Group. N Engl J Med. 1999;340:832-838PubMedGoogle Scholar
  107. 107.
    Sivilotti ML, Burns MJ, McMartin KE, et al. Toxicokinetics of ethylene glycol during fomepizole therapy: implications for manage-ment. For the Methylpyrazole for Toxic Alcohols Study Group. Ann Emerg Med. 2000;36:114-125PubMedGoogle Scholar
  108. 108.
    Lheureux P, Penaloza A, Gris, et al. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med. 2005;12:78-85PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • James F. Winchester
    • 1
  • Nikolas Harbord
    • 1
  • Donald A. Feinfeld
    • 1
  1. 1.Division of Nephrology & Hypertension, Baird HallBeth Israel Medical CenterNew YorkUSA

Personalised recommendations